Study Shows Biocept's Target Selector™ May Provide a More Robust Method for Detecting Lung Cancer Metastasis in Cerebrospinal Fluid than Cytology
Leptomeningeal metastasis is difficult to diagnose and assess for treatment response using conventional methods such as cytology. In this study, 28 cerebrospinal fluid samples from 15 patients obtained sequentially before and during treatment were compared. Target Selector™ improved detection of circulating tumor cells (CTC), finding CTCs in 78% of the samples, whereas cytology detected tumor cells in 55% of samples. Target Selector™ also provided sensitive quantitative identification of actionable EGFR mutations in cerebrospinal fluid. In patients with stable disease and partial response, Exon 19 deletion mutant copy numbers decreased, whereas they increased in a patient with progressive disease. Strikingly, alterations in CTC density (CTCs/mL) as well as in EGFR mutant copy numbers were observed weeks before a treatment response was measured via traditional clinical evaluations, such as the RECIST criteria.
"Even in this small study the ability to detect response to this experimental treatment in cerebrospinal fluid using Target Selector™ is promising, particularly as the diagnosis of leptomeningeal disease remains challenging using current methods," said
"These results indicate Target Selector™ may play an important role in providing valuable information to neuro-oncologists in making treatment decisions for patient with lung cancer metastases to the brain," said
About the IASLC 2020 Lung Cancer Hot Topic Meeting: Liquid Biopsy
There have been numerous advances in liquid biopsy since this event's advent in 2018, and the concept of a "blood-first" approach – superseding or replacing tissue biopsy – is a current topic of much debate and discussion. This innovative virtual conference brought together international and multidisciplinary experts in the field of liquid biopsy in lung cancer to present and discuss current technology and best practices for clinical applications based on available data.
About the IASLC
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the ability of our tests to provide clinically actionable information, the role Target Selector™ may plan in providing valuable information to neuro-oncologists in making treatment decisions for patient with lung cancer metastases to the brain, and the ability of
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-biocepts-target-selector-may-provide-a-more-robust-method-for-detecting-lung-cancer-metastasis-in-cerebrospinal-fluid-than-cytology-301145470.html